The letter of intent describes what the framework for the collaboration will look like and is a first step on the journey towards reaching a distribution agreement. EndoDrill GI, which has market clearance in both the US and Europe, is designed for early detection and diagnosis of gastrointestinal cancers such as pancreatic, gastric and esophageal cancer. The instrument is distinguished by its precision and ability to take high-quality tissue samples, which can improve diagnostics for patients.
BiBBInstrument’s first sale in the United States took place in January, with one of the country’s leading university hospitals, UC Davis Health, on the receiving end. Now, the company, together with TaeWoong Medical USA, is planning a targeted launch at selected hospitals in the fall of 2025, with a broader national rollout in 2026.
– This Letter of Intent marks an exciting and important step for BiBB. Following our first U.S. sale earlier this year, we are now positioned to accelerate our commercial journey in the world’s largest healthcare market, comments BiBBInstruments CEO Fredrik Lindblad. TaeWoong Medical USA is a fast-growing distributor with an innovative portfolio of therapeutic endoscopic ultrasound products, such as stents and RFA devices, and sees EndoDrill as a natural extension into diagnostic biopsy solutions. This makes them an ideal partner.
